Access to gene therapy for rare diseases when commercialization is not fit for purpose.
- DOI
- 10.1038/s41591-023-02208-8
- Published
- 2023 Mar
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-023-02208-8,
title = {Access to gene therapy for rare diseases when commercialization is not fit for purpose.},
author = {Fox T and Bueren J and Candotti F and Fischer A and Aiuti A and Lankester A and AGORA Initiative and Booth C},
year = {2023},
journal = {Nature medicine},
doi = {10.1038/s41591-023-02208-8},
url = {https://doi.org/10.1038/s41591-023-02208-8}
}RIS
TY - JOUR TI - Access to gene therapy for rare diseases when commercialization is not fit for purpose. AU - Fox T AU - Bueren J AU - Candotti F AU - Fischer A AU - Aiuti A AU - Lankester A AU - AGORA Initiative AU - Booth C PY - 2023 JO - Nature medicine DO - 10.1038/s41591-023-02208-8 UR - https://doi.org/10.1038/s41591-023-02208-8 ER -
APA
T, F., J, B., F, C., A, F., A, A., A, L., Initiative, A., & C, B. (2023). Access to gene therapy for rare diseases when commercialization is not fit for purpose.. Nature medicine. https://doi.org/10.1038/s41591-023-02208-8
Source records
- pubmed · retrieved 2026-09-26T18:54:28.646Z